TriSalus Life Sciences, Inc. Net Change in Cash
TriSalus Life Sciences, Inc. (TLSI) reported Net Change in Cash of $25.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-06
- TriSalus Life Sciences, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was $35.76M, a 699.20% increase year-over-year.
- TriSalus Life Sciences, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was $4.47M.
- TriSalus Life Sciences, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$7.81M.
- TriSalus Life Sciences, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$2.65M.
- TriSalus Life Sciences, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $11.91M.
- TriSalus Life Sciences, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$3.25M, a 232.03% decline from fiscal 2023.
- TriSalus Life Sciences, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $2.46M.
- TriSalus Life Sciences, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$20.64M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 4 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $25.50M 10-Q · filed 2026-08-06 | ||||||||
| 2026-03-31 | $35.76M 10-Q · filed 2026-05-12 | ||||||||
| 2025-12-31 | $11.91M 10-K · filed 2026-03-05 | ||||||||
| 2025-09-30 | $14.16M 10-Q · filed 2025-11-13 | ||||||||
| 2025-06-30 | $17.96M 10-Q · filed 2026-08-06 | ||||||||
| 2025-03-31 | $4.47M 10-Q · filed 2026-05-12 | ||||||||
| 2024-12-31 | -$3.25M 10-K · filed 2026-03-05 | ||||||||
| 2024-09-30 | -$489.00K 10-Q · filed 2025-11-13 | ||||||||
| 2024-06-30 | $4.70M 10-Q · filed 2025-08-12 | ||||||||
| 2024-03-31 | -$7.81M 10-Q · filed 2025-05-15 | ||||||||
| 2023-12-31 | $2.46M 10-K/A · filed 2025-05-30 | ||||||||
| 2023-09-30 | $11.97M 10-Q · filed 2024-11-14 | ||||||||
| 2023-06-30 | -$5.51M 10-Q · filed 2024-08-14 | -$49.59K 10-Q · filed 2023-08-02 | |||||||
| 2023-03-31 | -$2.65M 10-Q · filed 2024-05-15 | -$16.77K 10-Q · filed 2023-05-12 | |||||||
| 2022-12-31 | -$20.64M 10-K · filed 2024-04-11 | -$47.32K 10-K · filed 2023-03-22 | |||||||
| 2022-09-30 | -$17.96M 10-Q · filed 2023-11-14 | $6.71K 10-Q · filed 2022-11-10 | |||||||
| 2022-06-30 | -$131.70K 10-Q · filed 2023-08-02 | ||||||||
| 2022-03-31 | -$149.95K 10-Q · filed 2023-05-12 | ||||||||
| 2021-12-31 | -$1.13M 10-K · filed 2023-03-22 | ||||||||
| 2021-09-30 | -$1.06M 10-Q · filed 2022-11-10 | ||||||||
| 2021-06-30 | -$692.05K 10-Q · filed 2022-08-10 | ||||||||
| 2021-03-31 | -$205.85K 10-Q · filed 2022-05-11 | ||||||||
| 2020-12-31 | $1.33M 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |